Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amin Rostami

Showing results (111-120 of 306) with videos related to

Pageof 31
Sort By:
British Journal of Clinical Pharmacology|February 15, 2007
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an exampleGemma L Dickinson, Martin S Lennard, Geoffrey T Tucker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 20, 2004
Predicting the clearance of CYP2C9 substratesKaren Rowland Yeo, Eleanor M Howgate, Geoffrey T Tucker, et al.
The AAPS Journal|July 19, 2020
Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic ModelsDan Liu, Linzhong Li, Amin Rostami-Hodjegan, et al.
International Immunopharmacology|January 23, 2003
Influence of the thr164ile polymorphism in the beta2-adrenoceptor on the effects of beta-adrenoceptor agonists on human lung mast cellsLinda J Kay, Lee K Chong, Amin Rostami-Hodjegan, et al.
Clinical Pharmacokinetics|April 21, 2012
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modellingKhaled Abduljalil, Penny Furness, Trevor N Johnson, et al.
Drug Metabolism and Pharmacokinetics|May 30, 2016
Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro dataLu Gaohua, Sibylle Neuhoff, Trevor N Johnson, et al.
The AAPS Journal|June 18, 2016
Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought ProcessBipin Mistry, Nikunjkumar Patel, Masoud Jamei, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2022
Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5'-Diphosphate GlucuronosyltransferaseAnika N Ahmed, Amin Rostami-Hodjegan, Jill Barber, et al.
Biopharmaceutics & Drug Disposition|January 1, 2017
Quantifying gut wall metabolism: methodology mattersOliver J D Hatley, Christopher R Jones, Aleksandra Galetin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 5, 2017
Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing EnzymesBrahim Achour, Hajar Al Feteisi, Francesco Lanucara, et al.
Pageof 31

Showing results (111-120 of 306) with videos related to

Sort By:
Pageof 31
British Journal of Clinical Pharmacology|February 15, 2007
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an exampleGemma L Dickinson, Martin S Lennard, Geoffrey T Tucker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 20, 2004
Predicting the clearance of CYP2C9 substratesKaren Rowland Yeo, Eleanor M Howgate, Geoffrey T Tucker, et al.
The AAPS Journal|July 19, 2020
Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic ModelsDan Liu, Linzhong Li, Amin Rostami-Hodjegan, et al.
International Immunopharmacology|January 23, 2003
Influence of the thr164ile polymorphism in the beta2-adrenoceptor on the effects of beta-adrenoceptor agonists on human lung mast cellsLinda J Kay, Lee K Chong, Amin Rostami-Hodjegan, et al.
Clinical Pharmacokinetics|April 21, 2012
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modellingKhaled Abduljalil, Penny Furness, Trevor N Johnson, et al.
Drug Metabolism and Pharmacokinetics|May 30, 2016
Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro dataLu Gaohua, Sibylle Neuhoff, Trevor N Johnson, et al.
The AAPS Journal|June 18, 2016
Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought ProcessBipin Mistry, Nikunjkumar Patel, Masoud Jamei, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2022
Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5'-Diphosphate GlucuronosyltransferaseAnika N Ahmed, Amin Rostami-Hodjegan, Jill Barber, et al.
Biopharmaceutics & Drug Disposition|January 1, 2017
Quantifying gut wall metabolism: methodology mattersOliver J D Hatley, Christopher R Jones, Aleksandra Galetin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 5, 2017
Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing EnzymesBrahim Achour, Hajar Al Feteisi, Francesco Lanucara, et al.
Pageof 31